Ampakines (AMPA-PAM)Ampakine (AMPA-PAM)A positive allosteric modulator (PAM) of the AMPA glutamate receptor that enhances excitatory signalling.
Sunifiram vs Unifiram
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
| SSunifiram | UUnifiram | |
|---|---|---|
| What it is | Ampakine, AMPA-PAM, sub-mg active dose. | Ampakine (DM-232), alkynyl variant of Sunifiram, AMPA-PAM. |
| MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | AMPA-PAM + NMDA-glycine | AMPA-PAM (Sunifiram-like) |
| Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed. | No human data | No human data |
| Legal statusLegal / WADA statusThe compound’s regulatory status (e.g. prescription) and its place on the WADA prohibited-in-sport list. | Investigational, not approved | Investigational, not approved |
| Full entry | Open → | Open → |
What it is
SunifiramAmpakine, AMPA-PAM, sub-mg active dose.
UnifiramAmpakine (DM-232), alkynyl variant of Sunifiram, AMPA-PAM.
MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds).
SunifiramAMPA-PAM + NMDA-glycine
UnifiramAMPA-PAM (Sunifiram-like)
Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed.
SunifiramNo human data
UnifiramNo human data
Legal statusLegal / WADA statusThe compound’s regulatory status (e.g. prescription) and its place on the WADA prohibited-in-sport list.
SunifiramInvestigational, not approved
UnifiramInvestigational, not approved
Full entry